Camrose County seeks data on agricultural damage from Richardson's ground squirrels
The county wants data from farmers on damages and economic impacts from squirrel infestations. It intends to draft a report using the data to present to the federal government, for help controlling the ground squirrel population.
Alberta's Agricultural Service Board has noted an increase in Richardson's ground squirrel population, but has also acknowledged that little research has been done on where in the province they are problematic or best practices for population management.
Humphrey Banack, who owns a farm in the county about 80 kilometres southeast of Edmonton, said he has experienced reported significant losses
"They're voracious eaters. You know, they grow from the size of a small mouse to a rat in two months," he said.
So far, he's estimated that damages on his farm caused by the squirrels have reached around $20,000, across nearly 20 acres of destroyed crops.
Banack said he has considered ripping up the land where the rodents have burrowed, to start anew.
"Those costs are higher than our grain crop cost because we're going to pull some drills over and seed next year. There's not a bunch we have to do to manage their infested area in grain crops," he said.
"The best control we can have is shooting them or lead poisoning."
Strychnine ban
Farmers had traditionally used toxic substances like strychnine or anticoagulants to control pests on their land.
The federal government started to phase out the use of strychnine in 2020, and outright banned the substance by 2024. Health Canada found that strychnine uses did not meet the requirements for protection of the environment.
WATCH | Alberta urges feds to reinstate strychnine use:
Camrose County's survey to farmers states "this is an important chance to make sure Camrose County producers are heard at the federal level — especially following the ban on strychnine in 2023."
In a letter released in June, the Alberta government criticized the strychnine ban, stating that "the annual risk to hay and native pasture [due to damage caused by ground squirrels] exceeds $800 million."
The letter calls for the government to reinstate the use of the pesticide.
For wildlife biologist Gilbert Proulx, toxic substances like strychnine aren't all they're cracked up to be, when it comes to Richardson's ground squirrel.
Proulx, who is also the director of science at Alpha Wildlife, said these substances don't do much to decrease the population of Richardson's ground squirrels.
"It happens only when there's no more food to eat, and then the squirrel will eat the grains of strychnine," he said.
"But most squirrels will recognize they're feeding on something that is not that healthy, so a lot of them will stop."
He said in order to control the ground squirrel population, farmers need to eliminate at least 75 per cent of the population on or around their land.
Pesticides like strychnine also pose a threat to the predators of ground squirrels.
"They get killed by their predators and their predators die of secondary poisoning," Proulx said.
Proulx said need farmers need to be implementing year-round maintenance measures.
"The best is to maintain your fields that are at a proper level of vegetation. Encourage the predators to stay in your fields with rock piles so that they … can establish themselves. Those predators will do quite a dent in the population," he said
"It's no use to panic and put poison everywhere and kill the wrong species."
Banack said there is a risk of farmers and producers incorrectly using the pesticides. But, he said, when used properly, the substances could save farmers land and money.
"The vast majority of producers do understand that there are risks to using more potent stuff, but those risks can be very, very well managed from our end."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Medical Device Testing Market Size Attains USD 24.32 Bn by 2034
The global medical device testing market is valued at USD 10.77 billion in 2025 and is projected to grow to approximately USD 24.32 billion by 2034, expanding at a CAGR of 9.47% during the forecast period. Ottawa, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The global medical device testing market size was valued at USD 9.84 billion in 2024 and is projected to reach approximately USD 24.32 billion by 2034, expanding at a CAGR of 9.47% over the forecast period, according to a study published by Towards Healthcare, a sister firm of Precedence Research. A rise in the need for trustworthy and high-quality medical devices is propelling the expansion of the global market. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways Asia-Pacific led the global medical device testing market in 2024. North America is expected to witness rapid expansion during 2025-2034. By service, the biocompatibility tests segment was dominant in the market in 2024. By service, the chemistry tests segment is expected to register significant growth in the coming years. By phase, the clinical segment held the dominating share of the global medical device testing market in 2024. By phase, the preclinical segment is expected to grow at a notable CAGR during 2025-2034. Market Overview & Potential A process in which the evaluation of the safety, efficiency, and performance of medical devices is conducted, termed medical device testing. Across the globe, the global medical device testing market is experiencing growing regulatory strictness, technological breakthroughs, and a rising healthcare sector. In 2025, it comprises major developments in in-vitro diagnostics (IVD), and the execution of the EU's Medical Device Regulation (MDR) around the market. Usually, it encompasses the evaluation, functionality, durability, sterility, biocompatibility, electrical safety, and usability of the medical device. What are the Key Growth Drivers Involved in The Expansion of The Market? In 2025, several growth factors are impacting the overall development of the global medical device testing market. The growing geriatric population associated with chronic concerns is driving demand for diverse medical devices involved in diabetes management, mobility assistance, and remote patient monitoring. Along with this, an emerging strict regulatory landscape, such as the FDA and the EU's MDR, is offering strong testing guidelines for safety and efficacy. Majorly, different developing medical device producers, particularly startups, are highly outsourcing testing to specialized firms, resulting in market growth. Become a valued research partner with us - What are the Key Drifts Involved in the Market? In August 2025, BDC Laboratories, a leading player in cardiovascular device testing solutions, entered into a strategic partnership with the newly established Dilawri Cardiovascular Institute (DCI) to enhance focus on the development and clinical validation of cardiovascular medical devices. In October 2024, NAMSA, a leader in MedTech Contract Research Organization (CRO) offering end-to-end market access services, and TERUMO, a global player in medical technology, partnered to expand the regulatory approval and commercialization of Terumo's product portfolio. What is the Emerging Challenge in the Market? The need for significant investment in specialized equipment, skilled personnel, and ongoing compliance efforts is creating a major hindrance in the global medical device testing market. Alongside, the widespread requirement for specialized knowledge and skills in areas like biocompatibility, sterilization, and electrical safety is evolving into a barrier to the development of the market. Regional Analysis Why Did Asia Pacific Dominate the Market in 2024? Across the global medical device testing market, the Asia Pacific was dominant in 2024. China, India, and Japan are experiencing a vital expansion due to increasing economies and growing disposable incomes. This ultimately results in a rise in investment in the healthcare system and medical devices, propelling the adoption of various testing services. Additionally, faster advances in different technologies, such as miniaturization, digitalization, and the development of new materials, are enhancing the need for specialized testing March 2025, UL Solutions Inc., a major player in applied safety science, announced its expansion of Songshan Lake IoT Laboratory in Dongguan, China, to support manufacturers in navigating the complexities of connected product and wireless device testing and market access. What Made North America Significantly Grow in the Market in 2024? During 2025-2034, North America is predicted to expand at a rapid CAGR in the global medical device testing market. Merging high R&D investment by many medical device companies, like the adoption of technologies like AI and automation, in this region, is fueling overall market development. Also, North America is focusing on patient safety and regulatory compliance, especially in the US, which requires rigorous testing throughout the product January 2025, Argon Medical Devices enrolled the first patient in a US-based study exploring a newer catheter-based device for managing blood clots in the lungs. In June 2025, Ash, a leading at-home health testing platform, and Impilo, a leader in offering at-home healthcare, partnered to deliver feasible at-home health monitoring and testing nationwide. You can place an order or ask any questions, please feel free to contact us at sales@ Segmental Insights By service analysis Which Service Led the Medical Device Testing Market in 2024? The biocompatibility tests segment held the largest revenue share of the market in 2024. Around the globe, numerous medical device manufacturers are preferring biocompatibility testing to achieve market acceptance and develop a robust reputation for quality and safety. Along with this, these tests are important for reducing the risk of adverse reactions, infections, and other difficulties linked with medical devices. This leads to ensuring patient safety and improving device efficacy. Whereas the chemistry tests segment is predicted to grow rapidly during 2025-2034. Several advantages of this segment are the assessment of the possible toxicity of medical devices and confirming that they will not react negatively with the body. Additionally, the chemistry tests are widely employed in broader devices, from simple disposables to complex implants, to ensure their safety and regulatory compliance. Primarily, they comprise the identification of chemical compounds of a medical device and examination of probable risks linked with their presence, which further assist in biocompatibility assessment. By phase analysis How did the Clinical Segment Hold a Major Share of the Market in 2024? The clinical segment dominated the global medical device testing market in 2024. Usually, different phases of clinical trials offer significant real-world evidence that assists healthcare professionals in making informed decisions about device usage and expands the continuous optimization of medical devices. A surge in 3D printing and AI in medical device manufacturing is boosting the need for clinical trials to study the performance and safety of these new technologies. Also, the segment is driven by the accelerating need for advanced medical devices, a focus on patient safety and efficacy, and a rise in regulatory scrutiny. The preclinical segment is predicted to witness significant expansion in the studied years. Ongoing developments in biocompatibility testing, microbiology testing, and package validation are widely impacting the development of the preclinical phase of the market. Furthermore, various medical device industries, especially small-scale ones, have a shortage of resources or well-trained personnel to execute complete preclinical testing in-house. This further propels the demand for specialized preclinical testing service providers. Whereas, currently growing diverse chronic diseases are fueling demand for enhanced patient safety, which ultimately relies on the development of the preclinical phase. Get the latest insights on healthcare industry segmentation with our Annual Membership: Recent Developments In July 2025, Siemens Healthineers launched the CN-3000 and CN-6000 Hemostasis Systems for coagulation testing in Canada. In May 2025, Roche unveiled the Elecsys PRO-C3 test for the evaluation of the liver fibrosis severity in individuals with signs of metabolic dysfunction–associated steatotic liver disease (MASLD). In March 2025, Nelson Labs launched a groundbreaking rapid sterility testing to notably expedite product sterility results. In October 2024, UPM Biomedicals, the forerunner in producing high quality nanofibrillar cellulose for medical and life science applications, introduced FibGel, a natural injectable hydrogel for permanent implantable medical devices. Medical Device Testing Market Key Players SGS SA Laboratory Corporation of America Holdings Nelson Laboratories, LLC TÜV SÜD Charles River Laboratories Element Minnetonka North America Science Associates Inc. (NAMSA) Eurofins Scientific Pace Analytical Services LLC Intertek Group Plc WuXi AppTec Browse More Insights of Towards Healthcare: The global medical device contract manufacturing market is valued at USD 78.61 billion in 2024, expected to grow to USD 87.14 billion in 2025, and projected to reach approximately USD 220.57 billion by 2034, expanding at a CAGR of 10.86% between 2025 and 2034. The global medical device outsourcing market is estimated at USD 160.3 billion in 2024, rising to USD 180.59 billion in 2025, and forecasted to hit nearly USD 507.89 billion by 2034, advancing at a CAGR of 12.65% during 2025–2034. The global pain management devices market stands at USD 7.68 billion in 2024, increasing to USD 8.41 billion in 2025, and is anticipated to reach around USD 19.1 billion by 2034, growing at a CAGR of 9.54% over the forecast period. The global medical device CRO market is valued at USD 8.49 billion in 2024, set to rise to USD 9.25 billion in 2025, and projected to surpass USD 19.9 billion by 2034, at a CAGR of 8.98% between 2025 and 2034. The global wearable medical devices market is calculated at USD 42.78 billion in 2024, climbing to USD 53.68 billion in 2025, and expected to surge to nearly USD 408.61 billion by 2034, registering a strong CAGR of 25.57% from 2025 to 2034. The global implantable medical devices market is estimated at USD 97.17 billion in 2024, growing to USD 103.14 billion in 2025, and forecasted to reach around USD 176.33 billion by 2034, advancing at a CAGR of 6.14% during 2025–2034. The medical device gaskets & seals market was valued at USD 0.92 billion in 2023 and is projected to expand to USD 1.57 billion by 2034, progressing at a CAGR of 5% from 2024 to 2034. The 3D-printed medical devices market is expected to grow from USD 5.59 billion in 2025 to approximately USD 24.69 billion by 2034, witnessing a robust CAGR of 17.94% over the forecast period. The global endoscopy devices market size is valued at USD 61.1 billion in 2024, projected to increase to USD 63.44 billion in 2025, and estimated to reach USD 88.55 billion by 2034, registering a CAGR of 3.82% between 2025 and 2034. The global rehabilitation equipment market is valued at USD 17 billion in 2024, expected to rise to USD 18.42 billion in 2025, and projected to hit USD 37.34 billion by 2034, expanding at a CAGR of 8.34% from 2025 to 2034. Segments Covered in The Report By Service Biocompatibility Tests Cardiovascular Device's Biocompatibility Tests Orthopedic Device's Biocompatibility Tests Dental Implant Devices' Biocompatibility Tests Dermal Filler's Biocompatibility Tests General Surgery Implantation Devices Biocompatibility Tests Neurosurgical Implantation Devices Biocompatibility Tests Ophthalmic Implantation Device's Biocompatibility Tests Others Chemistry Test Chemical characterization (E&L) Analytical method development and validation Toxicological Risk Assessment and consulting Microbiology & Sterility Test Bioburden Determination Pyrogen & Endotoxin Testing Sterility Test & Validation Antimicrobial Testing Others Package Validation By Phase Preclinical Large animal research Biocompatibility Tests Chemistry Test Microbiology & Sterility Test Small animal research Biocompatibility Tests Chemistry Test Microbiology & Sterility Test Clinical By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region: +44 778 256 0738 North America Region: +1 8044 4193 44 APAC Region: +91 9356 9282 04 Web: Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | PinterestError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Health Canada grants marketing authorization for an additional indication of Bayer's NUBEQA® (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC)
Today's marketing authorization is based on recent results from the Phase III ARANOTE trial and broadens the indication profile of darolutamide in metastatic hormone-sensitive prostate cancer (mCSPC), enabling its use in combination with ADT, with or without chemotherapy (docetaxel) MISSISSAUGA, ON, Aug. 21, 2025 /CNW/ - Bayer Inc. is pleased to announce that Health Canada has granted marketing authorization for its oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide)1 for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). This marketing authorization is based on results from the pivotal2 Phase III ARANOTE trial, which showed that darolutamide plus ADT reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mCSPC. With this additional marketing authorization, darolutamide plus ADT is the first and only ARi indicated in Canada for the treatment of adult patients with mCSPC, either with or without docetaxel. In addition, darolutamide is approved for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. "This latest authorization reaffirms NUBEQA's role as a therapy for men with prostate cancer," said Shurjeel Choudhri, Senior Vice President and Head of Medical and Scientific Affairs for Bayer Canada. "We extend our thanks to the scientists, doctors, patients, and their families for their contributions that allowed us to offer this new treatment option for metastatic castration-sensitive prostate cancer." "Clinical data from the ARANOTE trial showed that darolutamide is both efficacious and well tolerated as a combination therapy with androgen-deprivation therapy," said Fred Saad, M.D., Professor and Chairman of Surgery and Director of Genitourinary Oncology at the University of Montreal Hospital Center (CHUM), and Principal Investigator of the ARANOTE trial. "Today's approval further expands options for how physicians can use Nubeqa in the treatment of mCSPC, giving them greater flexibility in choosing treatment plans for their patients." In Canada, prostate cancer is the most commonly diagnosed cancer among men, with an incidence rate of 119.7 cases per 100,000 men annually.3 Among those who are diagnosed, there is a portion of patients who will present with metastatic castration-sensitive prostate cancer (mCSPC), which may occur either de novo (newly diagnosed with metastatic disease) or as metachronous (recurrent disease following treatment for localized prostate cancer). In Canada, approximately 8.6% of all new prostate cancer cases are diagnosed as de novo mCSPC.4 Prognosis varies by disease stage, and while overall survival for prostate cancer is high, the 5-year net survival rate for patients with stage IV metastatic prostate cancer is approximately 41%, highlighting the need for optimized treatment strategies in this population. ² "Prostate cancer continues to have a significant impact on men and their families in Canada, with incidence and mortality rates that remain unacceptably high," said Dr. Stuart Edmonds, Executive Vice President for Mission, Research and Advocacy at the Canadian Cancer Society. "Bringing more treatments to patients faster offers new hope, greater choice, and the potential for improved outcomes." Darolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. About the ARANOTE TrialThe ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mCSPC. 669 patients were randomized 2:1 to receive 600 mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is rPFS (radiographic progression-free survival), measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to metastatic castration-resistant prostate cancer, time to initiation of subsequent systemic anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial were presented at ESMO 2024 and published in The Journal of Clinical Oncology. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people, and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to References: Nubeqa® Canadian Product Monograph Journal of Clinical Oncology: Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trialhttps:// Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2023. Toronto, Ontario: Canadian Cancer Society; 2023. Canadian Cancer Society. Survival statistics for prostate cancer. 2021; Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. ___________________ 1 Nubeqa® Canadian Product Monograph 2 Journal of Clinical Oncology: Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial 3 Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2023. Toronto, Ontario: Canadian Cancer Society;2023. 4 Canadian Cancer Society. Survival statistics for prostate cancer. 2021; SOURCE Bayer Inc. View original content to download multimedia:
Yahoo
4 hours ago
- Yahoo
Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance
Eligible Canadian patients with heterozygous familial hypercholesterolemia (HeFH) are one step closer to publicly funded access to cholesterol lowering treatment. MONTRÉAL, Aug. 21, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of Leqvio® (inclisiran) for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH), a genetic condition characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C), significantly increasing the risk of early cardiovascular events such as heart attack and stroke.1 "At HeartLife, we believe that people living with FH deserve timely access to the most effective therapies available," said Marc Bains, Co-Founder, HeartLife Foundation. "This agreement is an important step forward in closing long-standing gaps in care and expanding treatment options for patients who face a significantly higher risk of early heart disease. We are committed to working with partners across Canada to ensure these advances reach the people who need them most." "Familial Hypercholesterolemia is underdiagnosed and undertreated, despite the significant cardiovascular risk it carries," said Dr. Liam Brunham, Canada Research Chair and Associate Professor at University of British Columbia and Co-Lead of FH Canada. "For many patients with FH, it is challenging to control LDL-C levels with standard therapies. Having access to advanced therapies is an important advance in the treatment of these patients. The conclusion of pCPA negotiations for this therapy is a positive sign towards expanded access to treatment options and closing an important gap in care." "Concluding pCPA negotiations for Leqvio® is a significant moment for Canadians living with HeFH," said Mark Vineis, Country President, Novartis Pharmaceuticals Canada Inc. "We're committed to working with provincial and territorial partners to help ensure timely and equitable access to this treatment option for patients with elevated cardiovascular risk." Although this milestone represents meaningful progress, public reimbursement through provincial and territorial formularies has not yet been secured. As the next step, Novartis will collaborate with public drug programs towards timely access to treatment for eligible patients living with HeFH. About Leqvio® (inclisiran) Leqvio® is indicated as an adjunct to lifestyle changes, including diet, to further reduce LDL-C level in adults living with HeFH who are on maximally tolerated dose of a statin, with or without other LDL-C-lowering therapies. Leqvio® was first approved by Health Canada in 2021 based on clinical trials that demonstrated its efficacy to safely lower LDL cholesterol2,3,4 and received a positive funding recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) in 2021 for adults with HeFH. Since its commercialization in 2022, Leqvio® has made a difference in the lives of more than 4,500 Canadians and 290,000 patients worldwide.5 About Cardiovascular Disease (CVD) Cardiovascular diseases (CVD), including heart disease, stroke and vascular cognitive impairment, are responsible for the loss of one life every five minutes,6 and are the second leading cause of death in Canada after cancer.7 In Canada, heart disease is the leading cause of hospitalization among Canadian women, aside from giving birth,8 and within the Canadian healthcare system, CVD accounts for $22 billion annually.5 The five-year prevalence of ASCVD in Canada ranges between 6.91%-8.55% in adults.6,7 HeFH has an estimated prevalence of 1 in 250 to 311 individuals.9,10,11 About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit FA-11492432E______________________________1 What Is Heterozygous Familial Hypercholesterolemia? Family Heart. Accessed on August 8, 2025. Available at: What Is Heterozygous FH? | Family Heart Foundation2 ORION-9 (NCT NCT03397121). Accessed on August 8, 2025. Available at: 3 ORION-10 (NCT NCT03399370). Accessed on August 8, 2025. Available at: ORION-11 (NCT NCT03400800). Accessed on August 8, 2025. Available at: Novartis Data on file.6 2019 Heart & Stroke Report. Accessed on August 8, 2025. Available at: Heart Disease in Canada. Canada. Accessed on August 8, 2025. Available at: Jaffer S, Foulds HJA, Parry M, Gonsalves CA, Pacheco C, Clavel MA, Mullen KA, Yip CYY, Mulvagh SL, Norris CM. The Canadian Women's Heart Health Alliance ATLAS on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women-Chapter 2: Scope of the Problem. CJC Open. 2020 Oct 15;3(1):1-11. doi: 10.1016/ PMID: 33458627; PMCID: PMC7801195. Accessed on August 8, 2025.9 Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM et al. (2017) Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open 7 (9): e016461. Accessed on August 8, 2025.10 Hu P, Dharmayat KI, Stevens CA, Sharabiani MT, Jones RS et al. (2020) Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation 141 (22): 1742-1759. Accessed on August 8, 2025.11 Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG (2020) Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol 75 (20): 2553-2566. Accessed on August 8, 2025. SOURCE Novartis Pharmaceuticals Canada Inc. View original content to download multimedia: